Danaher Co. (NYSE:DHR – Get Free Report) has earned an average recommendation of “Moderate Buy” from the twenty-one research firms that are currently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a hold recommendation and sixteen have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $277.76.
DHR has been the topic of several research reports. JPMorgan Chase & Co. reduced their price target on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Stifel Nicolaus upgraded shares of Danaher from a “hold” rating to a “buy” rating and set a $260.00 target price on the stock in a research report on Friday, March 14th. Citigroup dropped their price target on Danaher from $285.00 to $265.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Wells Fargo & Company decreased their price objective on Danaher from $280.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Finally, The Goldman Sachs Group set a $250.00 target price on Danaher in a report on Wednesday, January 15th.
Read Our Latest Stock Analysis on Danaher
Insider Transactions at Danaher
Hedge Funds Weigh In On Danaher
Large investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in Danaher by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 59,750,122 shares of the conglomerate’s stock worth $13,715,641,000 after acquiring an additional 315,912 shares in the last quarter. FMR LLC lifted its stake in shares of Danaher by 15.8% during the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after buying an additional 3,217,631 shares during the period. Geode Capital Management LLC raised its stake in Danaher by 2.4% in the 4th quarter. Geode Capital Management LLC now owns 13,358,206 shares of the conglomerate’s stock worth $3,056,996,000 after acquiring an additional 315,446 shares during the last quarter. Norges Bank acquired a new position in shares of Danaher in the fourth quarter valued at about $2,130,740,000. Finally, Bank of New York Mellon Corp lifted its holdings in shares of Danaher by 5.4% during the fourth quarter. Bank of New York Mellon Corp now owns 8,589,019 shares of the conglomerate’s stock worth $1,971,609,000 after purchasing an additional 441,012 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.
Danaher Stock Up 0.1 %
DHR opened at $212.71 on Friday. The company has a market capitalization of $152.03 billion, a PE ratio of 40.29, a price-to-earnings-growth ratio of 2.66 and a beta of 0.82. The firm has a 50-day simple moving average of $219.04 and a two-hundred day simple moving average of $239.67. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher has a 52 week low of $196.80 and a 52 week high of $281.70.
Danaher (NYSE:DHR – Get Free Report) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter last year, the firm earned $2.09 earnings per share. Analysts forecast that Danaher will post 7.63 earnings per share for the current fiscal year.
Danaher Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.60%. The ex-dividend date of this dividend is Friday, March 28th. This is a boost from Danaher’s previous quarterly dividend of $0.27. Danaher’s dividend payout ratio is presently 24.24%.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- What is a SEC Filing?
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- What is Insider Trading? What You Can Learn from Insider Trading
- 3 Must-Own Stocks to Build Wealth This Decade
- How to Invest in Blue Chip Stocks
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.